These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

762 related articles for article (PubMed ID: 15561697)

  • 1. Deep venous thrombosis.
    López JA; Kearon C; Lee AY
    Hematology Am Soc Hematol Educ Program; 2004; ():439-56. PubMed ID: 15561697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral anticoagulant therapy in venous thromboembolism.
    Cosmi B; Palareti G
    Semin Vasc Med; 2003 Aug; 3(3):303-14. PubMed ID: 15199464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tinzaparin in outpatients with pulmonary embolism or deep vein thrombosis.
    Dager WE; King JH; Branch JM; Chow SL; Ferrer RE; Pak S; Togioka PY; White RH
    Ann Pharmacother; 2005; 39(7-8):1182-7. PubMed ID: 15956232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treating patients with cancer and acute venous thromboembolism.
    Donadini MP; Squizzato A; Ageno W
    Expert Opin Pharmacother; 2016; 17(4):535-43. PubMed ID: 26606049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-molecular-weight heparin in cancer-associated thrombosis: treatment, secondary prevention, and survival.
    Nishioka J; Goodin S
    J Oncol Pharm Pract; 2007 Jun; 13(2):85-97. PubMed ID: 17873108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of DVT: how long is enough and how do you predict recurrence.
    Agnelli G; Becattini C
    J Thromb Thrombolysis; 2008 Feb; 25(1):37-44. PubMed ID: 17906973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Venous thromboembolism and cancer: risks and outcomes.
    Lee AY; Levine MN
    Circulation; 2003 Jun; 107(23 Suppl 1):I17-21. PubMed ID: 12814981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of low-molecular-weight heparins as supportive care therapy in cancer-associated thrombosis.
    Cunningham RS
    Semin Oncol; 2006 Apr; 33(2 Suppl 4):S17-25; quiz S41-2. PubMed ID: 16638457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer-related deep venous thrombosis: clinical importance, treatment challenges, and management strategies.
    Deitcher SR
    Semin Thromb Hemost; 2003 Jun; 29(3):247-58. PubMed ID: 12888929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treating patients with venous thromboembolism: initial strategies and long-term secondary prevention.
    Huisman MV; Bounameaux H
    Semin Vasc Med; 2005 Aug; 5(3):276-84. PubMed ID: 16123915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Venous thromboembolism: risk factors for recurrence.
    Zhu T; Martinez I; Emmerich J
    Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):298-310. PubMed ID: 19228602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal duration of anticoagulation. Provoked versus unprovoked VTE and role of adjunctive thrombophilia and imaging tests.
    Prandoni P; Barbar S; Milan M; Campello E; Spiezia L; Piovella C; Pesavento R
    Thromb Haemost; 2015 Jun; 113(6):1210-5. PubMed ID: 25119194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation and management of chronic pulmonary thromboembolic disease.
    Mendoza V; Scharf ML
    Hosp Pract (1995); 2011 Aug; 39(3):50-61. PubMed ID: 21881392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute phase treatment of VTE: Anticoagulation, including non-vitamin K antagonist oral anticoagulants.
    Hillis C; Crowther MA
    Thromb Haemost; 2015 Jun; 113(6):1193-202. PubMed ID: 25948149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low molecular weight heparins: the optimal treatment for venous thromboembolism.
    Daskalopoulos ME; Daskalopoulou SS; Liapis CD
    Curr Med Res Opin; 2004 Jul; 20(7):1001-5. PubMed ID: 15265244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
    van Doormaal FF; Raskob GE; Davidson BL; Decousus H; Gallus A; Lensing AW; Piovella F; Prins MH; Büller HR
    Thromb Haemost; 2009 Apr; 101(4):762-9. PubMed ID: 19350123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism.
    Novacek G; Weltermann A; Sobala A; Tilg H; Petritsch W; Reinisch W; Mayer A; Haas T; Kaser A; Feichtenschlager T; Fuchssteiner H; Knoflach P; Vogelsang H; Miehsler W; Platzer R; Tillinger W; Jaritz B; Schmid A; Blaha B; Dejaco C; Eichinger S
    Gastroenterology; 2010 Sep; 139(3):779-87, 787.e1. PubMed ID: 20546736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Anticoagulation strategies in patients with deep vein thrombosis and pulmonary artery embolisms].
    Radke PW; Möckel M
    Herz; 2018 Feb; 43(1):34-42. PubMed ID: 29247268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enoxaparin in the treatment of deep vein thrombosis with or without pulmonary embolism: an individual patient data meta-analysis.
    Mismetti P; Quenet S; Levine M; Merli G; Decousus H; Derobert E; Laporte S
    Chest; 2005 Oct; 128(4):2203-10. PubMed ID: 16236875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of venous thromboembolism: adherence to guidelines and impact of physician knowledge, attitudes, and beliefs.
    Caprini JA; Tapson VF; Hyers TM; Waldo AL; Wittkowsky AK; Friedman R; Colgan KJ; Shillington AC;
    J Vasc Surg; 2005 Oct; 42(4):726-33. PubMed ID: 16242561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.